%PDF-1.4
%
1 0 obj
<>>>/BBox[0 0 584.96 782.99]/Length 134>>stream
x5;0Dޫ
?+!AQb#=qA3-7$vtd
[?aR\*坏OL>/bP8ձ)jR#iIXvծ 6'
endstream
endobj
9 0 obj
<>>>/BBox[0 0 584.96 782.99]/Length 134>>stream
x5;0Dޫ
?+!AQb#=qA3-7$vtd
[?aR\*坏OL>/bP8ձ)jR#iIXvծ 6'
endstream
endobj
5 0 obj
<>>>/BBox[0 0 584.96 782.99]/Length 134>>stream
x5;0Dޫ
?+!AQb#=qA3-7$vtd
[?aR\*坏OL>/bP8ձ)jR#iIXvծ 6'
endstream
endobj
6 0 obj
<>>>/BBox[0 0 584.96 782.99]/Length 134>>stream
x5;0Dޫ
?+!AQb#=qA3-7$vtd
[?aR\*坏OL>/bP8ձ)jR#iIXvծ 6'
endstream
endobj
10 0 obj
<>>>/BBox[0 0 584.96 782.99]/Length 134>>stream
x5;0Dޫ
?+!AQb#=qA3-7$vtd
[?aR\*坏OL>/bP8ձ)jR#iIXvծ 6'
endstream
endobj
7 0 obj
<>>>/BBox[0 0 584.96 782.99]/Length 134>>stream
x5;0Dޫ
?+!AQb#=qA3-7$vtd
[?aR\*坏OL>/bP8ձ)jR#iIXvծ 6'
endstream
endobj
3 0 obj
<>>>/BBox[0 0 584.96 782.99]/Length 134>>stream
x5;0Dޫ
?+!AQb#=qA3-7$vtd
[?aR\*坏OL>/bP8ձ)jR#iIXvծ 6'
endstream
endobj
8 0 obj
<>>>/BBox[0 0 584.96 782.99]/Length 134>>stream
x5;0Dޫ
?+!AQb#=qA3-7$vtd
[?aR\*坏OL>/bP8ձ)jR#iIXvծ 6'
endstream
endobj
12 0 obj
<>>>/BBox[0 0 584.96 782.99]/Length 134>>stream
x5;0Dޫ
?+!AQb#=qA3-7$vtd
[?aR\*坏OL>/bP8ձ)jR#iIXvծ 6'
endstream
endobj
11 0 obj
<>>>/BBox[0 0 584.96 782.99]/Length 134>>stream
x5;0Dޫ
?+!AQb#=qA3-7$vtd
[?aR\*坏OL>/bP8ձ)jR#iIXvծ 6'
endstream
endobj
4 0 obj
<>>>/BBox[0 0 584.96 782.99]/Length 134>>stream
x5;0Dޫ
?+!AQb#=qA3-7$vtd
[?aR\*坏OL>/bP8ձ)jR#iIXvծ 6'
endstream
endobj
14 0 obj
<>stream
Activity of Exebacase (CF-301) against Biofilms Formed by Staphylococcus epidermidis Strains Isolated from Prosthetic Joint Infections
10.1128/aac.00588-22
Aubin Souche
Camille Kolenda
Jordan Teoli
Raymond Schuch
Tristan Ferry
Frédéric Laurent
Jérôme Josse
Experimental Therapeutics
Experimental Therapeutics
CF-301
biofilms
exebacase
prosthetic joint infections
Staphylococcus epidermidis
American Society for Microbiology
American Society for Microbiology
Copyright © 2022 American Society for Microbiology.
All Rights Reserved.
20220711
2022
ABSTRACT
Staphylococcus epidermidis is one of the main pathogens responsible for bone and joint infections, especially those involving prosthetic materials, due to its ability to form biofilms. In these cases, biofilm formation, combined with increased antimicrobial resistance, often results in therapeutic failures. In this context, the development of innovative therapies active against S. epidermidis is a priority. The aim of this study was to evaluate the in vitro activity of the lysin exebacase (CF-301) against biofilms formed by 19 S. epidermidis clinical strains isolated from prosthetic joint infections (PJI). We determined the biomass and the remaining viable bacteria inside biofilms after 24 h of exposure to exebacase. Exebacase activity was compared to that of rifampicin, vancomycin, and daptomycin. The use of exebacase in addition to antibiotics was also assessed. Exebacase displayed (i) a significant anti-biomass activity on S. epidermidis biofilms at concentrations ≥5 mg/L (mean decrease up to 66% at 150 mg/L), (ii) significant bactericidal activity on biofilms at concentrations ≥50 mg/L (mean decrease up to 1.7 log CFU at 150 mg/L), (iii) synergistic effects when used in addition to rifampicin, vancomycin, or daptomycin. The extent of these activities varied by isolate. Exebacase can be considered a promising therapy in addition to rifampicin, vancomycin, or daptomycin in the context of PJI. Further in vitro studies are needed to understand its mechanism of action on S. epidermidis biofilms and in vivo investigations are required to confirm these data.
20220504
20220621
1098-6596
Adobe LiveCycle PDF Generator; modified using iText® 5.5.13.2 ©2000-2020 iText Group NV (AGPL-version)2022-08-02T06:38:44-07:00
endstream
endobj
15 0 obj
<>stream
x+ |
endstream
endobj
16 0 obj
<>stream
xS**T0T0 Bi y\'
endstream
endobj
17 0 obj
<>stream
x+ |
endstream
endobj
18 0 obj
<>stream
xS**T0T0 Bi yS&
endstream
endobj
19 0 obj
<>stream
x+ |
endstream
endobj
20 0 obj
<>stream
xS**T0T0 Bi y+
endstream
endobj
21 0 obj
<>stream
x+ |
endstream
endobj
22 0 obj
<>stream
xS**T0T0 Bi y8#
endstream
endobj
23 0 obj
<>stream
x+ |
endstream
endobj
24 0 obj
<>stream
xS**T0T0 Bih lT
endstream
endobj
25 0 obj
<>stream
x+ |
endstream
endobj
26 0 obj
<>stream
xS**T0T0 Bi yA$
endstream
endobj
27 0 obj
<>stream
x+ |
endstream
endobj
28 0 obj
<>stream
xS**T0T0 Bi yw*
endstream
endobj
29 0 obj
<>stream
x+ |
endstream
endobj
30 0 obj
<>stream
xS**T0T0 Bi yJ%
endstream
endobj
31 0 obj
<>stream
x+ |
endstream
endobj
32 0 obj
<>stream
xS**T0T0 Bi yn)
endstream
endobj
33 0 obj
<>stream
x+ |
endstream
endobj
34 0 obj
<>stream
xS**T0T0 Bi ye(
endstream
endobj
35 0 obj
<>stream
x+ |
endstream
endobj
36 0 obj
<>stream
xS**T0T0 Bi y,
endstream
endobj
38 0 obj
<>stream
HWےT[$Q.*1)XpH" wA*U[==}9}?ޫo;uRNҴwEj*o=<xe2ɢm?v5KXOnhÈIYRN#]89!nGM&1E)1E_?Si T?ߐ<
p>ԃ,o6N+>Sxb/d@YE8C2@{*VY}ٻ&ZUD~~xovPNF^ɓmjn|
T+FTd0Q)>EgG<^H4urw53
` DER$/3x桗`R:O:kad'EN1Yg3
@q~ RFP[
9eU)b4-Kxi|ʔڮmMdzLD4r>Lms&MJRXh%iS@1ve'!}9C۹C9!zhD;,Q!>҆GOdcӂelxԡ黉
JsΜKkЙ.X5o4oۙ:9ŏWG7<ͽ,F5h
.x̢{r$S5L ҹS]Kd?ŵ$ι$"UEk2D